Breaking News Instant updates and real-time market news.

CBAY

CymaBay

$5.54

-5.545 (-50.05%)

, GNFT

Genfit

$20.42

-3.33 (-14.02%)

10:26
06/11/19
06/11
10:26
06/11/19
10:26

Piper cuts CymaBay price target to $8 on 'worst case' results for NASH trial

Piper Jaffray analyst Tyler Van Buren said he did not anticipate that placebo would perform better than seladelpar in CymaBay Therapeutics' (CBAY) Phase 2b study of the drug for the treatment of nonalcoholic steatohepatitis. Calling the NASH trial results a "worst case scenario," Van Buren sees significant risk to the final 52-week data read-out and removed all expectations in NASH from his model. He said the data make seladelpar seem similar to Genfit's (GNFT) elafibranor, though seladelpar has not yet shown improvements in good cholesterol, glucose homeostatis, or insulin resistance. While Van Buren cut his price target on CymaBay shares to $8 from $30 based on the trial results, he keeps an Overweight rating on the shares given the sharp pullback this morning and the support he sees from the company's remaining cash and residual opportunity.

CBAY

CymaBay

$5.54

-5.545 (-50.05%)

GNFT

Genfit

$20.42

-3.33 (-14.02%)

  • 12

    Jun

CBAY CymaBay
$5.54

-5.545 (-50.05%)

06/07/19
LEER
06/07/19
NO CHANGE
Target $22
LEER
Outperform
FDA news has 'nothing to do' with CymaBay's programs, says SVB Leerink
SVB Leerink analyst Pasha Sarraf says that CymaBay Therapeutics is down on an "overreaction" to the FDA's recommendation regarding endpoint for compensated cirrhosis. In a research note to investors , Sarraf says he recommends purchasing at these levels, saying he continues to believe the the stock is likely to pop on the interim results from the MRI-PDFF results, which have not yet been announced and feels the FDA's announcement regarding compensated cirrhosis has "absolutely nothing to do" with CymaBay's programs. Sarraf has an Outperform rating and $22 price target on CymaBay shares.
05/14/19
SBSH
05/14/19
INITIATION
Target $21
SBSH
Buy
CymaBay initiated with a Buy at Citi
Citi analyst Joel Beatty started CymaBay Therapeutics (CBAY) with a Buy rating and $21 price target. The analyst believes the company's seladelpar will "likely dethrone" Intercept Pharmaceuticals' (ICPT) Ocaliva as the top-selling branded primary biliary cholangitis drug. Topline results for seladelpar in PBC are anticipated in 2021 and the analyst sees a 75% probability of approval.
04/15/19
CANT
04/15/19
NO CHANGE
Target $20
CANT
Overweight
Genfit data show CymaBay may be differentiated, says Cantor Fitzgerald
Further competitor primary biliary cholangitis data from Genfit's (GNFTF) elafibranor suggest CymaBay Therapeutics' (CBAY) seladelpar may have a differentiated profile, Cantor Fitzgerald analyst Eliana Merle tells investors in a research note. The analyst keeps an Overweight rating on CymaBay with a $20 price target.
03/01/19
PIPR
03/01/19
NO CHANGE
Target $30
PIPR
Overweight
Piper Jaffray loves the setup for CymaBay shares into NASH data
CymaBay's Seladelpar has made "tremendous progress" in primary biliary cholangitis over the past year its competitive positioning continues to improve, Piper Jaffray analyst Tyler Van Buren tells investors in a research note. Further, the analyst believes the drug's nonalcoholic steatohepatitis opportunity is not currently being factored into the existing valuation. The analyst expects to receive topline data from the ongoing Phase IIb trial of seladelpar in NASH next quarter. If successful, it could "multiply" the $750M PBC opportunity in his model, Van Buren says in a research note titled "We Love The Setup Of CBAY Here; Reiterate The Overweight." He keeps a $30 price target on CymaBay shares.
GNFT Genfit
$20.42

-3.33 (-14.02%)

05/14/19
HCWC
05/14/19
NO CHANGE
HCWC
H.C. Wainwright affirms Buy on Genfit after positive recommendation from DSMB
H.C. Wainwright analyst Ed Arce affirmed a Buy rating and $72 price target on Genfit after the company announced that the the Data Safety Monitoring Board, or DSMB, of the Phase 3 RESOLVE-IT trial of elafibranor for the treatment of NASH, or nonalcoholic steatohepatitis, had "rendered a positive recommendation for the trial's continuation without any changes. This 36-month safety review is the sixth planned review by the DSMB, and revealed no safety issues with elafibranor." The analyst estimates elafibranor's probability of success at 75% for NASH and 60% for PBC, and utilize a 11.5% discount rate, which he believes is "appropriate for a small-cap development stage biotech."
04/24/19
LEER
04/24/19
INITIATION
Target $58
LEER
Outperform
Genfit initiated with an Outperform at SVB Leerink
SVB Leerink analyst Pasha Sarraf started Genfit with an Outperform rating and $58 price target. The analyst's core thesis in obesity-induced metabolic liver diseases, including nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, is the utility of combining therapies that provide metabolic, and anti-inflammatory/fibrotic benefits on a background of practical weight loss therapies. Genfit's elafibranor may become one of the first products entering the market that fits this thesis with reproducibly meaningful lipid and triglyceride lowering benefits, insulin sensitization and reduction of glycated hemoglobin, and impact on inflammatory hepatic pathology, Sarraf tells investors in a research note.
04/22/19
HCWC
04/22/19
NO CHANGE
Target $72
HCWC
Buy
Genfit price target lowered to $72 from EUR 105 at H.C. Wainwright
H.C. Wainwright analyst Ed Arce lowered his price target for Genfit to $72 from EUR 105 citing the impact of the 24.5% share dilution from the company's recent global offering. The new target, however, still represents about 188% upside from current levels and an implied market capitalization of $2.8B, Arce tells investors in a research note. With Genfit's Nasdaq listing complete, investor focus sharpens on nonalcoholic steatohepatitis and primary biliary cholangitis, adds the analyst. He keeps a Buy rating on the stock.
04/22/19
LEHM
04/22/19
INITIATION
Target $55
LEHM
Overweight
Genfit initiated with an Overweight at Barclays
Barclays analyst Geoff Meacham started Genfit with an Overweight rating and $55 price target. Despite the challenges in nonalcoholic steatohepatitis, Genfit's pipeline offers "compelling opportunities," which creates an attractive risk/reward profile for the stock, Meacham tells investors in a research note.

TODAY'S FREE FLY STORIES

VTR

Ventas

$69.65

1.05 (1.53%)

21:28
06/19/19
06/19
21:28
06/19/19
21:28
Upgrade
Ventas rating change at Stifel »

Stifel upgrades to Ventas…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$197.87

-0.65 (-0.33%)

21:22
06/19/19
06/19
21:22
06/19/19
21:22
Initiation
Apple initiated at Deutsche Bank »

Apple initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

DELL

Dell Technologies

$53.39

1.88 (3.65%)

21:22
06/19/19
06/19
21:22
06/19/19
21:22
Initiation
Dell Technologies initiated at Deutsche Bank »

Dell Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

HPQ

HP Inc.

$20.63

0.1 (0.49%)

21:21
06/19/19
06/19
21:21
06/19/19
21:21
Initiation
HP Inc. initiated at Deutsche Bank »

HP Inc. initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 01

    Jul

  • 02

    Jul

  • 03

    Jul

  • 04

    Jul

GNCA

Genocea

$3.84

-1.32 (-25.58%)

21:18
06/19/19
06/19
21:18
06/19/19
21:18
Syndicate
Genocea 10M share Secondary priced at $3.50 »

SVB Leerink and Stifel…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

PSNL

Personalis

$0.00

(0.00%)

21:15
06/19/19
06/19
21:15
06/19/19
21:15
Syndicate
Personalis 7.922M share IPO priced at $17.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

CYRX

Cryoport

$18.62

-0.08 (-0.43%)

21:13
06/19/19
06/19
21:13
06/19/19
21:13
Syndicate
Cryoport 3.75M share Spot Secondary priced at $17.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

VTR

Ventas

$69.65

1.05 (1.53%)

20:41
06/19/19
06/19
20:41
06/19/19
20:41
Upgrade
Ventas rating change at Stifel »

Ventas upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HSY

Hershey

$137.94

-0.29 (-0.21%)

20:27
06/19/19
06/19
20:27
06/19/19
20:27
Downgrade
Hershey rating change at Piper Jaffray »

Hershey downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KR

Kroger

$23.64

-0.3 (-1.25%)

, DRI

Darden

$117.55

-0.39 (-0.33%)

20:25
06/19/19
06/19
20:25
06/19/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

KR

Kroger

$23.64

-0.3 (-1.25%)

DRI

Darden

$117.55

-0.39 (-0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 20

    Jun

  • 25

    Jun

  • 27

    Jun

DAL

Delta Air Lines

$56.38

0.33 (0.59%)

20:08
06/19/19
06/19
20:08
06/19/19
20:08
Periodicals
Breaking Periodicals news story on Delta Air Lines »

Delta working on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

SPY

SPDR S&P 500 ETF Trust

$293.02

0.69 (0.24%)

, SPX

S&P 500

$0.00

(0.00%)

20:00
06/19/19
06/19
20:00
06/19/19
20:00
Periodicals
Breaking Periodicals news story on SPDR S&P 500 ETF Trust, S&P 500 »

Trump not planning to…

SPY

SPDR S&P 500 ETF Trust

$293.02

0.69 (0.24%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARZGY

Generali

$0.00

(0.00%)

19:22
06/19/19
06/19
19:22
06/19/19
19:22
Downgrade
Generali rating change at JPMorgan »

Generali downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GO

Grocery Outlet

$0.00

(0.00%)

19:00
06/19/19
06/19
19:00
06/19/19
19:00
Syndicate
Grocery Outlet 17.19M share IPO priced at $22.00 »

The deal priced above the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 20

    Jun

WIX

Wix.com

$145.83

1.19 (0.82%)

18:57
06/19/19
06/19
18:57
06/19/19
18:57
Hot Stocks
Wix.com CEO: Q1 was very good for us »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AOBC

American Outdoor Brands

$9.17

0.13 (1.44%)

, ORCL

Oracle

$52.69

-0.19 (-0.36%)

18:44
06/19/19
06/19
18:44
06/19/19
18:44
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS:…

AOBC

American Outdoor Brands

$9.17

0.13 (1.44%)

ORCL

Oracle

$52.69

-0.19 (-0.36%)

JSYN

Jensyn Acquisition

$5.00

-5.02 (-50.10%)

ABEO

Abeona Therapeutics

$4.90

-0.09 (-1.80%)

PIR

Pier 1 Imports

$0.67

-0.0059 (-0.87%)

SCS

Steelcase

$17.80

0.235 (1.34%)

LAND

Gladstone Land

$12.29

0.39 (3.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 19

    Jun

  • 19

    Jun

  • 20

    Jun

  • 24

    Jun

  • 26

    Jun

  • 26

    Jun

  • 10

    Jul

  • 20

    Jun

TMUS

T-Mobile

$78.28

1.79 (2.34%)

, S

Sprint

$7.46

0.24 (3.32%)

18:39
06/19/19
06/19
18:39
06/19/19
18:39
Periodicals
T-Mobile readies for Boost auction if Dish talks fall through, Reuters says »

T-Mobile (TMUS) is…

TMUS

T-Mobile

$78.28

1.79 (2.34%)

S

Sprint

$7.46

0.24 (3.32%)

DISH

Dish

$38.90

-0.18 (-0.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZBRA

Zebra Technologies

$200.57

-1.1 (-0.55%)

18:39
06/19/19
06/19
18:39
06/19/19
18:39
Hot Stocks
Zebra Technologies Chief of Product sells 5K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZBRA

Zebra Technologies

$200.57

-1.1 (-0.55%)

18:23
06/19/19
06/19
18:23
06/19/19
18:23
Hot Stocks
Zebra Technologies CEO sells 20K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNH

UnitedHealth

$250.25

4.6 (1.87%)

, DVA

DaVita

$51.27

1.51 (3.03%)

18:13
06/19/19
06/19
18:13
06/19/19
18:13
Hot Stocks
FTC approves UnitedHealth's acquisition of DaVita Medical with conditions »

Healthcare provider and…

UNH

UnitedHealth

$250.25

4.6 (1.87%)

DVA

DaVita

$51.27

1.51 (3.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

SRRK

Scholar Rock

$17.11

-2.835 (-14.21%)

18:11
06/19/19
06/19
18:11
06/19/19
18:11
Syndicate
Scholar Rock 3M share Secondary priced at $15.00 »

The deal priced below the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

QDEL

Quidel

$58.80

1.7 (2.98%)

18:01
06/19/19
06/19
18:01
06/19/19
18:01
Hot Stocks
Quidel receives 510k clearance for Triage TOX Drug Screen »

Quidel Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DELL

Dell Technologies

$53.39

1.88 (3.65%)

, HPQ

HP Inc.

$20.63

0.1 (0.49%)

17:59
06/19/19
06/19
17:59
06/19/19
17:59
Periodicals
Dell, HP, Intel, Microsoft express opposition to Trump tariffs, Bloomberg says »

Dell Technologies (DELL),…

DELL

Dell Technologies

$53.39

1.88 (3.65%)

HPQ

HP Inc.

$20.63

0.1 (0.49%)

INTC

Intel

$47.08

-0.29 (-0.61%)

MSFT

Microsoft

$135.63

0.43 (0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 23

    Jun

  • 28

    Jun

  • 01

    Jul

  • 02

    Jul

  • 03

    Jul

  • 04

    Jul

  • 09

    Jul

  • 09

    Jul

  • 10

    Jul

  • 25

    Jul

  • 06

    Aug

ORCL

Oracle

$52.69

-0.19 (-0.36%)

17:54
06/19/19
06/19
17:54
06/19/19
17:54
Hot Stocks
Oracle says 20% of Autonomous Database customers new to company »

Says plans to launch free…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

CB

Chubb

$149.48

1.37 (0.92%)

17:54
06/19/19
06/19
17:54
06/19/19
17:54
Hot Stocks
Chubb CEO sells 215.6K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.